CTOR earnings analysis
What we found in CTOR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
2026Q2 revenue fell 50% sequentially to $2.0 million from $4.0 million, while gross margin was broadly stable at 80.3%. Operating margin worsened to negative 1,716.2% from negative 133.2%, and diluted EPS declined to negative $0.27 from negative $0.06. The filing provides no numeric guidance and highlights substantial financing risks, including a 12.75% minimum interest rate, a $1,062,500 maturity payment, milestone-dependent funding tranches, and potential conversion of up to $4.0 million of debt.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined 50% sequentially
- Revenue was $2.0 million in 2026Q2, down approximately 50% from $4.0 million in 2026Q1. The filing data provided does not include a comparable prior-year quarterly revenue figure.
- Gross margin remained stable
- Gross margin was 80.3% in 2026Q2 versus 80.0% in 2026Q1, an improvement of 0.3 percentage points despite lower revenue.
- Operating losses sharply worsened
- Operating margin deteriorated to negative 1,716.2% in 2026Q2 from negative 133.2% in 2026Q1, a decline of 1,583.0 percentage points.
- EPS loss expanded materially
- Diluted EPS was negative $0.27 in 2026Q2 versus negative $0.06 in 2026Q1, a $0.21 per-share sequential deterioration.
- Disclosure controls remained effective
- The company states that disclosure controls were effective as of June 30, 2026, and that there were no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High-cost debt and balloon payment
- The Loan Agreement carries a floating interest rate with a floor of 12.75% per annum. The company also must make a final payment of $1,062,500 at maturity, creating a balloon obligation that may pressure liquidity.
- Future funding depends on milestones
- Availability of Tranche 2 and Tranche 3 is conditioned on achieving specified net revenue and liquidity milestones. Failure to meet those milestones would eliminate access to additional committed capital and could impair ongoing operations and working capital funding.
- Loan conversion creates dilution risk
- Lenders may convert up to $4.0 million of outstanding principal into common stock at $1.08 per share, while lender warrants equal 10% of funded loan portions and are exercisable at $0.90 per share, creating meaningful potential dilution.
- Broad collateral lien raises default risk
- The Loan Agreement is secured by a first-priority lien on substantially all assets, including intellectual property, accounts receivable, inventory, equipment, and general intangibles. A default could allow foreclosure on the company’s core operating assets.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.27
- Gross margin
- 80.3%
- Operating margin
- -1716.2%
What they said about what is next.
The filing provides no explicit numeric revenue or EPS guidance; quantitative outlook was not provided in the extracted MD&A.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Citius Oncology recorded product revenues of $1,667,298 in Q1 2026, marking a strong gross profit margin of approximately 80%. Despite this revenue growth, the company reported significant net losses of $26,609,695 due…
- 10-Q · February 13, 2026
- Citius Oncology reported first commercial revenue of $3,944,111 for Q1 (period ended December 31, 2025) following the December 2025 launch of LYMPHIR, yielding gross profit of $3,154,903 (80.0% gross margin). Despite…
- 10-Q · August 9, 2024
- Citius Oncology (formerly TenX Keane) remains a pre‑combination SPAC with no operating revenues. Investments held in the trust fell to $49,152,639 at June 30, 2024 from $72,565,394 at December 31, 2023 (driven by…
- 10-Q · May 20, 2024
- TenX Keane (CTOR) reported no operating revenue (SPAC) and generated net income of $489,829 for the quarter ended March 31, 2024, driven by interest on trust assets. Investments held in the trust fell materially to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CTOR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever